Hyperopia

Eyeglasses wear showed no major efficacy compared with observation in treating young children diagnosed with hyperopia, according to findings published in Ophthalmology.

In recent years, there has been a clear trend toward lens-based rather than cornea-based refractive surgery for moderate to high hyperopes. This is due in part to recognition of the limitations of corneal optics in hyperopic LASIK and the increased chance of hyperopic regression.

It remains unclear whether children 1 to 2 years old with moderate hyperopia definitively benefit from hyperopic correction.

Patients who underwent cataract surgery showed increased anterior chamber depth postoperatively, which correlated with refractive error.

The prevalence of pterygium was associated with short axial length and anterior chamber depth in a Chinese retrospective, hospital-based, cross-sectional study.

European authorities have granted a CE mark approval to STAAR Surgical’s ICL as a supplemental or “piggyback” lens in post-cataract IOL surgery, according to a press release.

The recently published WHO World Report on Vision is required reading for anyone interested in reducing the burden of vision impairment in the world, whether government agency, nongovernment agency, eye care provider, member of industry, investor or philanthropist.

Like any other part and function of the body, the eye and vision change over time. In the last two decades, advanced solutions have been developed to meet the needs of individuals at each stage of this process, allowing them to maintain healthy eyesight and enhance quality of life through spectacle-free vision. With such a wide spectrum of options available, it makes sense now to overcome fragmentation and give patients what they need at different stages of ocular maturity within the framework of a lifetime plan for vision.

I like the concept of lifetime management of refractive errors. I have a few thoughts as to how this might be accomplished.

Hyperopic and presbyopic treatment with the Technolas Teneo excimer laser from Bausch + Lomb, using two different algorithms in the dominant and nondominant eyes, showed safety, efficacy and stability at 24 months.